CTLA4 and melanoma: Ezh2 inactivation reversed this resistance and synergized with anti-CTLA-4 and IL-2 immunotherapy to lead to intratumorally accumulation of IFN-γ-producing PD-1low CD8+ T cells and PD-L1 downregulation to suppress melanoma growth [40].